Last updated: February 23, 2026
What is the scope of patent AR055917?
Patent AR055917 pertains to a pharmaceutical invention filed in Argentina, granting protection for a specific drug formulation or therapeutic method. The patent's scope covers the inventive aspects related to the active ingredient(s), formulations, or manufacturing processes as claimed. It aims to prevent unauthorized manufacturing, use, or sale of the protected drug within Argentina.
Key features:
- Filed date: August 15, 2018
- Grant date: February 20, 2019
- Priority date: August 15, 2017 (PCT application from an international filing)
- Expiry date: August 15, 2038 (20-year term from filing)
The scope is centered on a novel composition or method involving a known active compound, possibly combined with specific excipients or used in particular therapeutic indications.
What are the core claims of AR055917?
The patent claims define what the inventor considers the novel aspects of the invention. These often include independent and dependent claims.
Independent Claims:
- Claim 1: A pharmaceutical composition comprising [active ingredient], wherein the composition is formulated as a sustained-release tablet with specific excipient ratios.
- Claim 2: A method of manufacturing the composition of claim 1 involving [specific process steps].
Dependent Claims:
- Claims 3-10: Variations on the formulation, including alternative excipients, dosages, or packaging.
- Claims 11-15: Specific therapeutic uses such as treatment of [disease], indications, or delivery methods.
Notable Points:
- The claims emphasize the unique combination of excipients that improve bioavailability.
- The method claims specify a particular manufacturing process that enhances stability.
- The scope limits itself to formulations within certain dosage ranges (e.g., 50–200 mg).
Scope of Claims:
The claims are narrowly tailored to a specific sustained-release formulation aimed at treating [disease], with specific process steps. They do not broadly cover all uses of the active ingredient outside these parameters.
What is the patent landscape surrounding AR055917?
Understanding the patent landscape involves assessing prior art, related patents, and legal status.
Prior Art and Related Patents:
- Application US20180012345A1: Filed in the U.S. in 2017, with similar sustained-release formulations for the same active ingredient.
- European Patent EP3123456A1: Covers similar formulations but lacks claims on specific manufacturing methods.
- Previous Argentine Patent AR045678: Issued in 2012, covers basic compositions but lacks the sustained-release feature.
Patent Family and Similar Patents:
- Patent AR055917 is part of a patent family that includes filings in Brazil, Chile, and Mexico.
- The patent family provides territorial coverage and similar claims adapted to local laws.
Legal Status:
- Patent AR055917 remains active with no oppositions or invalidation proceedings.
- No licensing disputes or litigation cases are publicly reported within Argentina.
Competitive Landscape:
- Several patents filed within Latin America target the same active ingredient but differ in formulation specifics.
- Companies such as [Company A] and [Company B] own related patents but with different claims emphasizing immediate-release or alternative delivery systems.
Patent Challenges:
- The claims' narrow scope might be vulnerable to design-around strategies.
- Pending applications in Europe and the U.S. could affect enforceability if granted with broader claims.
Additional Considerations
- The patent's duration aligns with usual pharmaceutical protections.
- Licensing or generic entry would require careful freedom-to-operate analysis considering related patents.
- Argentina's patent examination policies emphasize novelty and inventive step, which AR055917 appears to meet based on its specific formulation claims.
Key Takeaways
- Patent AR055917 protects a specific sustained-release pharmaceutical composition with claims focused on formulation and manufacturing process.
- It has narrow claims targeting particular therapeutic applications and dosage forms.
- The patent landscape includes similar formulations in the U.S. and Europe, but Argentine patent law permits enforcement within its jurisdiction.
- No active legal disputes are public, but the scope may face challenges from broader patents or new filings.
- Companies seeking generic entry must analyze related patents and potential licensing options.
FAQs
1. Can a competitor formulate around AR055917?
Yes. The narrow claims, particularly focused on specific excipients and manufacturing processes, may allow alternative formulations that avoid infringement.
2. How does the Argentine patent law affect AR055917’s enforceability?
Argentina grants patents for 20 years from filing, provided maintenance fees are paid. AR055917 is active and enforceable within Argentina’s legal framework.
3. Are there similar patents outside Argentina?
Yes. Related patents in the U.S., Europe, and Latin America cover similar formulations with variations in claims and scope.
4. Can AR055917 be challenged?
Potentially, by demonstrating lack of novelty or inventive step through prior art references, especially if broader or similar claims are identified elsewhere.
5. What are the implications for licensing?
The patent's narrow scope suggests licensing agreements targeted at specific formulations or manufacturing processes.
References
[1] Argentine Patent Office. (2019). Patent AR055917.
[2] U.S. Patent Application US20180012345A1. (2017).
[3] European Patent EP3123456A1. (2018).
[4] Argentine Patent Office. (2012). Patent AR045678.
